GE Introduces Discovery LS

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 9
Volume 10
Issue 9

WAUKESHA, Wisconsin-GE Medical Systems, a unit of General Electric Company, has introduced the GE Discovery LS. The digital system combines anatomical imaging from the company’s fast CT scanner, the GE LightSpeed Plus, with functional imaging of metabolic activity from its most advanced positron emission tomography (PET) system, the GE Advance NXi.

WAUKESHA, Wisconsin—GE Medical Systems, a unit of General Electric Company, has introduced the GE Discovery LS. The digital system combines anatomical imaging from the company’s fast CT scanner, the GE LightSpeed Plus, with functional imaging of metabolic activity from its most advanced positron emission tomography (PET) system, the GE Advance NXi.

The Discovery LS generates high-quality PET and CT images of a patient in a single 30-minute examination. Two image data sets are registered and fused to form a single image.

The Discovery LS is currently installed for clinical use at University Hospital, Zurich, Switzerland; Johns Hopkins Medical Institutions; and Rambam Medical Center, Haifa, Israel. GE forecasts that 30 systems will be installed worldwide by the end of this year and more than 500 in the next 3 years.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content